Tectonic Therapeutic, Inc.
TECXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeTectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). The $594.3M market capitalization puts TECX squarely in small-cap range for its industry. It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines.
Market Cap
$594.3M
Beta
0.22
P/E (TTM)
—
P/E (Fwd)
-6.50
EPS (TTM)
$-4.57
EPS (Fwd)
$-4.68
ROE
-33.8%
ROA
-22.3%
Cash
$227.1M
Total Debt
$4.4M
Free CF
-$46.7M
52W Change
77.6%
Annual Financials
Cash vs Debt
Where TECX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, TECX finished 2.32% above its 150-day moving average ($29.69) and 11.53% above its 200-day moving average ($27.24). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TECX overbought or oversold?
At the September 3, 2026 close, TECX's RSI(14) was 41.6, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Tectonic Therapeutic, Inc. holds $227.1M in cash against $4.4M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$46.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -33.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The relatively low beta of 0.22 suggests TECX is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing TECX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.